Home Treatment Management Contact Us

Zoltan Kiss CanCureLab
A Family Company



Muscle Protein Loss in Cancer

During tumor development many, but not all, cancer patients unintentionally lose a significant portion of their body weight along with also losing muscle proteins resulting in reduced muscle strength; this syndrome called cancer cachexia directly responsible for about 30% of all cancer deaths. A typical cachectic cancer patient is shown below.

Of the two major characteristics of cancer cachexia, losing muscle strength, due to losing muscle proteins, is the most important. In order to develop a treatment to reduce or prevent the loss of muscle proteins and reduction of muscle strength, one has to know at what stage of tumor development that process starts and if it occurs in all cancer patients regardless of loss of body weight. In today’s medical practice no treatment is available to deal with early onset of muscle loss partly due to the absence of answers to those questions. Zoltan Kiss CanCureLab (in short, CanCure), a family-owned biotechnological company, set out to tackle these questions and found not only the answers but also a treatment opportunity.